- Molecular NameCyclophosphamide
- Synonymcyclophosphamide
- Weight261.089
- Drugbank_IDDB00531
- ACS_NO50-18-0
- Show 2D model
- LogP (experiment)0.63
- LogP (predicted, AB/LogP v2.0)0.8
- pkaN/A
- LogD (pH=7, predicted)0.8
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-0.81
- LogSw (predicted, AB/LogsW2.0)96.69
- Sw (mg/ml) (predicted, ACD/Labs)40.67
- No.of HBond Donors1
- No.of HBond Acceptors4
- No.of Rotatable Bonds5
- TPSA51.38
- StatusFDA approved
- AdministrationOral, intravenous
- PharmacologyA nitrogen mustard alkylating agent,
- Absorption_valueN/A
- Absorption (description)Well absorbed after oral administration.
- Caco_2N/A
- Bioavailability74.0
- Protein binding13.4
- Volume of distribution (VD)0.78 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe parent drug is inactive, but is converted into active metabolites by the liver. The drug and metabolites are widely distributed in the body. It is oxidised to 4-hydroxycyclophosphamide, which is in equilibrium with aldophosphamide, both of which are cytotoxic. 4-Hydroxycyclophosphamide can be oxidised further to 4-ketocyclophosphamide (inactive). Aldophosphamide may be converted to the cytotoxic metabolites phosphoramide mustard and acrolein, or oxidised to inactive carboxyphosphamide. Carboxyphosphamide may be converted to nornitrogen mustard, an active alkylating agent at acid pH.
- Half life7.5 h
- ExcretionUp to 95% of a dose is excreted in the urine, mostly during the first 48 h, with up to 25% as unchanged drug and the rest as metabolites. Small amounts are excreted in the bile and faeces.
- Urinary Excretion6.5
- Clerance1.3 ml/min/kg.
- Toxicityinfection, myelosuppression, and cardiac toxicity
- LD50 (rat)LD50=160
- LD50 (mouse)LD50=620 (injection)